An observational study in Chronic Myeloid Leukemia in Myeloid Blast Crisis, sponsored by University of Jena. Recruiting at 9 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-10.
Sponsored by University of Jena · Observational
Multicentric prospective and retrospective register collecting patient with CML blast crisis diagnosed in Germany and Europe
Since the advent of treatment with tyrosine kinase inhibitors (TKI), the incidence of blast crises has significantly decreased. Nevertheless, about 5% of patients diagnosed with chronic myeloid leukemia (CML) will evolve into a blast phase at some point during the course of their disease. Furthermore, despite the advances made in CML treatment, outcome of patients with blast crises are still dismal. Due to the rarity of this condition clinical trials are challenging, and collaboration between researchers both at national and international level is needed to collect a meaningful number of data.
Patients with CML Blast crisis, either newly diagnosed or as evolution of a CML in chronic phase
Diagnosis of BCR-ABL positive CML blast crisis according to the WHO criteria:
Exclusion Criteria:
Overall survival
how many patients survive after a blast crisis event
Time frame: through study completion in 2024
Rate of hematologic response to treatment
how many patients have a hematologic response to the local standard Treatment after a blast crisis event
Time frame: through study completion in 2024
Rate of molecular response to treatment
how many patients have a molecular response to the local standard Treatment after a blast crisis event
Time frame: through study completion in 2024
Rate of blast crises in Europe in the era of TKI treatment
how many patients have blast crisis events compared to all treated CML-patients in the trial centers
Time frame: through study completion in 2024
Plan to share: No — A joint publication is planned. But no data of trial Centers will be shared with the other trial centers.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive→
University of Jena